Dr. Ahn on the Significance of the KEYNOTE-177 Trial in mCRC

Video

In Partnership With:

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC).

The new standard of care for patients with MSI-H mCRC is based on findings from the KEYNOTE-177 trial, which were presented during the 2020 ASCO Virtual Scientific Program, says Ahn.

The study showed a doubling in progression-free survival with pembrolizumab (Keytruda) versus standard chemotherapy in patients with newly diagnosed MSI-H mCRC, Ahn explains.

Prior to these data, a patient with MSI-H mCRC ​that harbors an NTRK fusion would have ​received chemotherapy in the frontline setting, followed by either a checkpoint inhibitor or an ​NTRK-directed TKI​, says Ahn.

However, pembrolizumab monotherapy has now become the new frontline standard of care for ​this subgroup ofpatients, Ahn concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD